

Crystal structure, Hirshfeld surface analysis, and molecular dynamics simulations of two isostructural N-propargyl-4-(2-oxopyrrolidin-1-yl)-1,2,3,4-tetrahydroquinolines

- Güiza F.M.^a
- Rodríguez-Núñez Y.A.^b
- Ramírez D.^c
- Romero Bohórquez A.R.^a
- Henao J.A.^d
- Toro R.A.^d
- Delgado J.M.^e
- Díaz de Delgado G.^e

Abstract

Two new N-propargyl-4-(2-oxopyrrolidin-1-yl)-1,2,3,4-tetrahydroquinoline derivatives (4a and 4b), have been efficiently prepared through a one-pot InCl_3 -catalyzed cationic Povarov reaction between N-propargylanilines (1a and 1b), formaldehyde (2) and N-vinyl-pyrrolidin-2-one (3). These compounds were characterized by ATR-FTIR spectroscopy, $^1\text{H}/^{13}\text{C}$ NMR spectroscopy, ESI-IT mass spectrometry, and by single-crystal X-ray diffraction. N-propargyl-6-methyl-4-(2'-oxopyrrolidin-1'-yl)-1,2,3,4-tetrahydroquinoline (4a) and N-propargyl-6-chloro-4-(2'-oxopyrrolidin-1'-yl)-1,2,3,4-tetrahydroquinoline (4b) are isostructural and crystallize in space group $\text{P2}_1/\text{c}$. The crystal structures are characterized by inversion-related interpenetrated helices along the b-axis that form columns along the c-axis. $\text{C}-\text{H}\cdots\text{O}$, $\text{C}-\text{H}\cdots\text{C}$, and $\text{C}-\text{H}\cdots\pi(\text{aryl})$ for 4a and $\text{C}-\text{H}\cdots\text{O}$, $\text{C}-\text{H}\cdots\text{Cl}$, and $\text{C}-\text{H}\cdots\pi(\text{aryl})$ for 4b interactions occur within the columns which are connected by $\text{C}-\text{H}\cdots\pi(\text{propargyl})$ interactions. These features were further visualized by Hirshfeld surface analysis and energy frameworks calculations and evaluated by the E_{XY} enrichment ratio. Molecular dynamics simulations show that these compounds are promising monoamine oxidase B (MAO-B) inhibitors, since they interact with MAO-B in a similar manner as rasagiline, a drug commonly used in the treatment of Parkinson's and Alzheimer's diseases. © 2021

Author keywords

Cationic Povarov reaction; Crystal structure; Molecular dynamics simulations; Monoamine oxidase B inhibitors; N-propargylamines; Tetrahydroquinoline